IgA Nephropathy Drug Pipeline to Include 25+ Companies by 2025
Market research firm ResearchAndMarkets.com has released a new report detailing the IgA nephropathy (IgAN) drug development landscape through 2025. The analysis covers over 25 companies and more than 30 pipeline drug candidates.
ResearchAndMarkets.com has published a new report, "IgA Nephropathy- Pipeline Insight, 2025," offering a comprehensive outlook on the drug development status for IgA nephropathy (IgAN).
The report analyzes the pipelines of over 25 pharmaceutical companies, identifying more than 30 drug candidates currently under development. These potential treatments span various stages, from early preclinical research to advanced clinical trials.
IgA nephropathy, also known as Berger's disease, stands as the most prevalent primary glomerulonephritis. It is a condition that can escalate to end-stage renal disease (ESRD), characterized by the deposition of IgA antibodies in the kidney's glomeruli, an autoimmune response that impairs renal function.
The "IgA Nephropathy- Pipeline Insight, 2025" report provides detailed profiles of these pipeline drugs, including their mechanism of action, clinical and non-clinical data, and assessments based on product type, developmental stage, route of administration, and molecule type. It also identifies previously considered but discontinued pipeline products within the IgAN space.